Verax Biomedical Renews Commercialization Agreement with Fresenius Kabi USA for Platelet PGD® Test for Bacteria

Verax PGD® test is the industry standard for platelet safety

Jul 22, 2015, 08:30 ET from Verax Biomedical Incorporated

MARLBOROUGH, Mass., July 22, 2015 /PRNewswire-USNewswire/ -- Verax Biomedical today announced it has renewed its exclusive worldwide commercialization agreement with Fresenius Kabi USA focused on improving blood collection, separation, safety and availability. The agreement is to market, sell and distribute Verax's unique PanGenera® Detection (PGD) test - a rapid in vitro diagnostic test used to detect bacterial contaminants in donated platelets. The Verax Platelet PGD® test is the only rapid test on the market cleared by the FDA for all commonly available U.S. platelet types.

"Verax Platelet PGD® test is the industry standard when it comes to the detection of bacteria in platelets, and we are pleased to continue our partnership with Fresenius Kabi to combat the severe risk of bacterial contamination in the U.S. blood supply - the number one infectious risk to platelet transfusion recipients," said Verax Biomedical CEO Jim Lousararian. "Fresenius Kabi is a leader in the development of products that improve blood collection and safety worldwide, and we look forward to continuing our work with them to improve health care outcomes by reducing transfusion reactions associated with bacterial contamination."

"The Verax Platelet PGD® test is an essential safety tool that every hospital should use before transfusions," said Dean Gregory, president, Medical Devices, Fresenius Kabi USA.  "This agreement reaffirms our commitment to Verax technology, and is yet another example of how we are supporting improved safety in transfusion medicine."

The Verax PGD® test, based on proprietary technology developed by Verax, consists of an easy-to-use disposable test device and reagents that work together to detect the presence of bacterial contaminants in platelets. The test can be performed in less than 30 minutes and is designed for use in hospitals, cancer centers and other sites of care as a safeguard prior to transfusion.

Annually, more than 6 million platelet doses are transfused worldwide, and approximately 1 in 2,000 doses are contaminated by bacteria. The presence of bacteria in platelets can pose serious risks for patients, including sepsis—a life-threatening infection in the blood stream. The test is a cost effective approach to platelet bacterial safety.

About Verax Biomedical
Verax Biomedical Inc. is a leading developer of rapid tests for detecting bacterial contaminants in blood cells and tissue. The privately held company was founded in 1999. Its headquarters and laboratory facilities are in Worcester, Massachusetts. For more information, visit www.veraxbiomedical.com.

About Fresenius Kabi USA
Fresenius Kabi USA (www.fresenius-kabi.us) specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. The company's U.S. headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Hamburg, Germany.

 

SOURCE Verax Biomedical Incorporated



RELATED LINKS

http://www.veraxbiomedical.com